EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AFT Pharmaceuticals's enterprise value is A$295.8 Mil.
AFT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was A$19.5 Mil. Therefore, AFT Pharmaceuticals's EV-to-EBITDA for today is 15.21.
The historical rank and industry rank for AFT Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ASX:AFP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.74 Med: 19.01 Max: 63.97
Current: 15.56
During the past 8 years, the highest EV-to-EBITDA of AFT Pharmaceuticals was 63.97. The lowest was -28.74. And the median was 19.01.
ASX:AFP's EV-to-EBITDA is ranked worse than 52.26% of 708
companies
in the Drug Manufacturers industry
Industry Median: 14.76
vs ASX:AFP: 15.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
AFT Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for AFT Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AFT Pharmaceuticals's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's EV-to-EBITDA falls into.
AFT Pharmaceuticals's current Enterprise Value is A$295.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was A$19.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AFT Pharmaceuticals's PE Ratio for today is calculated as:
AFT Pharmaceuticals's share price for today is A$2.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was A$0.096.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of AFT Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
AFT Pharmaceuticals (ASX:AFP) Business Description
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:AFP has been successfully added to your 